Full-Process Compliance Solution for Import Agency of Original American Antibodies

Background and Common Difficulties of Importing Original American Antibodies

In 2026,the demand for high-end reagents in China’s biomedical R&D sector continues to grow.Among them,original American antibodies have become the first choice of many research institutions and pharmaceutical companies due to mature technology and strong specificity.However,importing such biological products is not easy,and many enterprises have encountered many problems in operation.For example,Mr.He from a biomedical company in Shanghai once encountered a thorny issue: Last year,his company needed to import a batch of monoclonal antibodies from a well-known American brand for pre-clinical trials of new drugs.The original plan was to complete the import within 3 weeks,but due to non-compliant documents in actual operation,the shipment was detained at the port for nearly 20 days,which almost affected the experimental progress.Once the experimental progress is delayed,the subsequent clinical application plan will also be postponed,and the loss is immeasurable.

Core Role of Zhongshen in Antibody Import

As an enterprise deeply engaged in foreign trade agency in Shanghai for over 20 years,Zhongshen has accumulated targeted experience in the field of biological product import.For special products such as original American antibodies,Zhongshen’s core role is to help enterprises sort out full-process compliance requirements,avoid risks in advance,and compress the import cycle to a controllable range.For example,Mr.He’s company later cooperated with Zhongshen.Zhongshen intervened in the whole process starting from document pre-audit,and finally completed customs clearance in only 7 days,catching up with the experimental progress.In Mr.He’s words: "When I handled it by myself before,I only had a half understanding of FDA’s document requirements and the details of domestic commodity inspection.After hiring an agent,someone follows the whole process,which saves a lot of trouble."

Process Decomposition and Compliance Handling for Importing Original American Antibodies

1.Document Pre-Audit Stage: Avoid China-US Compliance Conflicts in Advance

The first key link of importing original American antibodies is document pre-audit,which involves US FDA’s export requirements and China’s import document requirements.If there is a conflict or information missing between the two,all subsequent links will be stuck.For example,FDA’s export certificate needs to include the specific product batch,manufacturer’s qualification number,product expiration date,antibody target information,etc.And domestic commodity inspection authorities also require that this information is completely consistent with the third-party test report provided subsequently.

Zhongshen’s operation at this stage is: Contact American suppliers in advance,review FDA export certificate,product quality test report,certificate of origin and other documents provided by them.If incomplete information or non-compliant format is found,it will be fed back to the supplier for adjustment in a timely manner.For example,the FDA export certificate provided by Mr.He’s company previously lacked the manufacturer’s FDA registration number.After Zhongshen found it in advance,it assisted the supplier to contact the US FDA to complete the relevant information,avoiding subsequent return and re-issuance.

2.Port Customs Declaration Stage: Accurate Classification and Rapid Declaration

Port customs declaration is one of the core links of antibody import,and the key here is accurate classification of customs codes.Original American antibodies belong to biological products,and customs codes have clear subdivisions — for example,antibodies for scientific research and antibodies for clinical diagnosis have different codes,and there are slight differences in tariff rates (In 2026,the tariff rate for research-use antibodies is 0,and that for clinical-use antibodies is 3%).If the classification is wrong,it will not only delay customs clearance time,but also may face the problem of tariff supplementary payment.

Zhongshen’s customs declaration team is familiar with the customs code rules for biological products,and will accurately determine the code according to the antibody’s specific use (research/clinical),composition,target and other information.At the same time,Zhongshen maintains long-term smooth communication with the customs authorities of Shanghai Port,and can quickly submit declaration materials and speed up the review.For example,in Mr.He’s case,Zhongshen accurately classified it as 9307000090 according to the antibody’s use for scientific research,and it passed customs review in only 2 days after declaration,while it was returned 3 times due to code error when self-declared before.

3.Commodity Inspection Stage: Align with Domestic Quarantine Requirements for Biological Products

As a biological product,original American antibodies must pass the quarantine approval of the local Entry-Exit Inspection and Quarantine Bureau when imported.The requirements include: the product must meet domestic biosafety standards,at least 3 product samples must be provided for activity detection,and it can only be released after passing the test.Many enterprises do not understand quarantine requirements,such as sample storage temperature (requires 2-8℃ cold chain transportation),test items (purity,endotoxin content,etc.),leading to multiple submissions and time delays.

Zhongshen’s assistance in the commodity inspection stage includes: inform the enterprise of the required number of samples and test items in advance,connect with the inspection process of the commodity inspection department,and even assist the enterprise to book test time (In 2026,the antibody test appointment period for commodity inspection at Shanghai Port is about 3 days,Zhongshen can help enterprises shorten it to 1 day).For example,the sample prepared by Mr.He’s company previously had decreased activity due to improper cold chain transportation.After Zhongshen reminded in advance,it guided the company to use professional cold chain boxes for transportation,and the test passed at the first attempt,avoiding the time waste of re-submission.

Actual Case: Import Experience of Mr.He’s Company

Mr.He from a biomedical company in Shanghai needed to import a batch of brand-name American monoclonal antibodies (target PD-1) in March 2026,for pre-clinical efficacy trials of new drugs.Initially,Mr.He’s company tried to import by itself,and encountered two core problems:

• The FDA export certificate provided by the American supplier lacked the manufacturer’s FDA registration number,so it was returned by domestic port customs,and reprocessing took 7 days;
• The sample activity test was found unqualified during commodity inspection (because 2-8℃ cold chain was not maintained during self-transportation),so it was necessary to replenish samples,which took another 10 days.

The two delays resulted in the entire import process taking 22 days,and almost missed the experimental time agreed with the CRO company.Later,Mr.He contacted Zhongshen,and project director Supervisor Xiao connected with his needs.Supervisor Xiao’s operation steps were:

• First reviewed all documents from the American supplier,after finding the problem with the FDA export certificate,assisted the supplier to contact the US FDA to complete the registration number;
• Inform the required number of samples (5 copies) and cold chain requirements for commodity inspection in advance,guided Mr.He’s company to use professional cold chain boxes for transportation;
• Accurately classified the customs code during declaration,and synchronized the commodity inspection appointment,so that customs declaration and commodity inspection were promoted simultaneously.

In the end,this batch of antibodies completed customs clearance in only 7 days,catching up with the experimental progress.Mr.He later said: "When we did it by ourselves before,we didn’t understand many details.After working with Zhongshen,someone follows every link the whole time,we only need to provide basic information,which saves both trouble and time."

Comparison Between Self-Import and Agency Import

Many enterprises are torn between self-import and hiring an agency when importing original American antibodies.Based on years of experience,Zhongshen has sorted out the comparison between the two:

Conclusion: The Value of Zhongshen for Antibody Import

In 2026,the import demand of original American antibodies is still growing,but compliance requirements are also constantly updated (for example,FDA added the disclosure requirement for antibody target information in 2026).As an enterprise deeply engaged in foreign trade agency for over 20 years,Zhongshen can help enterprises:

• Sort out full-process compliance requirements,avoid risks in advance;
• Compress import cycle,avoid delays in experiments or production;
• Save internal labor costs,allow enterprises to focus on core business.

For biomedical enterprises,choosing a professional agency can not only improve import efficiency,but also reduce compliance risks.After all,import delay of high-end reagents such as antibodies not only brings time loss,but also may cause missing market opportunities.The core value of Zhongshen is to help enterprises turn these "uncontrollable" links into "controllable" and make the import process smoother.